Skip to content
Screener

CorMedix CRMD Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$39.7MMiss by $2.7M
EPS$0.28Beat by $0.08
Revenue estimate$42.5M
EPS estimate$0.20

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$53.3M
EPS estimate-$0.10

Financials

Q2 2025

Income statement

See full
Revenue$39.7M+4,829%
Gross profit$37.9M+12,683%
Operating income$19.5M+228%
Net income$19.8M+240%
EPS (diluted)$0.28+212%

Balance sheet

See full
Cash & equivalents$159.4M+457%
Total debt$435.0K-26.8%
Total equity$220.6M+378%
Total assets$252.6M+338%

Cash flow

See full
Operating cash flow$30.0M+314%
CapEx$24.0K-31.0%
Free cash flow$30.0M+313%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.07B+348%
Enterprise value$907.22M+332%
P/S8.8×—

Profitability

See full
Gross margin95.7%—
FCF margin25%—

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio7.8×+3.0×

Segments

By product

See full
DefenCath$39.7M+266%
Contract revenue-—
Grant income-—
Melinta Portfolio-—

FAQ

When did CorMedix report Q2 2025 earnings?
CorMedix (CRMD) reported Q2 2025 earnings on August 7, 2025 before market open.
What were CorMedix's Q2 2025 revenue and EPS?
CorMedix reported revenue of $39.7M and eps of $0.28 for Q2 2025.
Did CorMedix beat estimates in Q2 2025?
Revenue missed the consensus estimate of $42.5M by $2.7M. EPS beat the consensus estimate of $0.20 by $0.08.
How did CorMedix's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4829.4% from $806.1K a year earlier.
Where can I find CorMedix's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001213900-25-072814) and the 10-Q periodic report (0001213900-25-072843) directly on SEC EDGAR. The filing index links above go to sec.gov.